Unknown PHASE2 INTERVENTIONAL 2-arm NCT02618824

Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery

Sponsor: National Cardiovascular Center Harapan Kita Hospital Indonesia

Interventions Histidine Tryptophan Ketoglutarate Solution Terminal Warm Blood Cardioplegia

Updated 6 times since 2017 Last updated: Feb 17, 2016 Started: Dec 31, 2015 Primary completion: Aug 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Congenital Heart Disease, this trial is ongoing. The trial is conducted by National Cardiovascular Center Harapan Kita Hospital Indonesia and has accumulated 6 data snapshots since 2015. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE2

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cardiovascular Center Harapan Kita Hospital Indonesia

Data source: National Cardiovascular Center Harapan Kita Hospital Indonesia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jakarta, Indonesia